Moreover, tumor-promoting functions were blocked by anti-EREG antibodies or an EGFR-tyrosine kinase inhibitor (EGFR-TKI, gefitinib or erlotinib) in NSCLC [80]. The gene discussed is EREG; the disease is neoplasm.